Last updated: September 4, 2026
Losartan potassium and hydrochlorothiazide is a mature, generic antihypertensive combination marketed originally as Hyzaar by Merck. Its composition, regulatory exclusivity, and principal patent barriers have expired in the United States. The product now competes primarily on price, wholesaler access, manufacturing reliability, and formulary position rather than patent differentiation.
The financial trajectory is therefore structurally different from a branded pharmaceutical. Merck’s historical Cozaar and Hyzaar franchise generated substantial pre-generic revenue, but current sales are distributed among multiple generic manufacturers and are not generally reported as a standalone market by public companies. Volume remains supported by hypertension prevalence, while unit prices and manufacturer margins remain constrained by generic competition.
What is losartan potassium and hydrochlorothiazide?
Losartan potassium and hydrochlorothiazide combines an angiotensin II receptor blocker, losartan, with a thiazide diuretic, hydrochlorothiazide.
| Attribute |
Product information |
| Active ingredients |
Losartan potassium and hydrochlorothiazide |
| Original brand |
Hyzaar |
| Original innovator |
Merck & Co. |
| Therapeutic class |
Antihypertensive combination |
| Primary indications |
Hypertension; reduction of stroke risk in certain hypertensive patients with left ventricular hypertrophy |
| Common strengths |
50/12.5 mg, 100/12.5 mg, 100/25 mg |
| Dosage form |
Oral tablet |
| FDA approval |
Hyzaar NDA approved in the 1990s; current FDA labeling governs approved indications |
| Current status |
Generic and multisource product |
| Prescription status |
Prescription-only medicine |
Losartan blocks the AT1 receptor, reducing angiotensin II-mediated vasoconstriction and aldosterone activity. Hydrochlorothiazide increases renal sodium and water excretion. The combination can provide greater blood-pressure reduction than either component alone for appropriate patients.
The FDA-approved labeling identifies hypertension as the principal use and includes a stroke-risk indication for certain patients with hypertension and left ventricular hypertrophy. The label also identifies risks including hypotension, impaired renal function, electrolyte abnormalities, hyperuricemia, and fetal toxicity during pregnancy (U.S. Food and Drug Administration [FDA], n.d.-a).
How large is the losartan hydrochlorothiazide market?
The market is large in prescription volume but low in branded economic value. Losartan and hydrochlorothiazide are both long-established generic medicines, and most commercial activity is tied to recurring chronic prescriptions rather than new patient acquisition.
Demand drivers
Key demand drivers include:
- High global prevalence of hypertension.
- Continued use of combination therapy to improve blood-pressure control.
- Preference for single-tablet regimens among patients taking multiple medicines.
- Low acquisition cost for health plans and pharmacies.
- Continued use in patients already stabilized on losartan-based therapy.
The product competes in a broad hypertension market that includes losartan monotherapy, other ARBs, ACE inhibitors, calcium-channel blockers, beta blockers, and fixed-dose combinations containing other ARBs with hydrochlorothiazide.
Demand constraints
Demand is limited by:
- Availability of lower-cost separate tablets.
- Substitution by newer fixed-dose ARB combinations.
- Clinical concerns involving hydrochlorothiazide, including electrolyte effects and photosensitivity.
- Reimbursement formularies that prefer alternative ARBs or generic single-agent therapy.
- Product recalls or shortages affecting specific manufacturers rather than the entire molecule class.
The product remains clinically relevant, but its market position is primarily defensive and maintenance-oriented.
What is the financial trajectory for losartan potassium and hydrochlorothiazide?
The financial trajectory has three phases: branded expansion, patent-driven erosion, and generic stabilization.
| Period |
Financial pattern |
Main driver |
| Pre-generic period |
High branded revenue and substantial margin |
Hyzaar and Cozaar franchise growth |
| Generic-entry period |
Rapid revenue and price erosion |
Multiple ANDA approvals and formulary substitution |
| Mature generic period |
Stable prescription demand with low per-unit economics |
Commodity pricing and manufacturing scale |
Merck historically reported Cozaar and Hyzaar as a combined franchise rather than consistently disclosing Hyzaar sales as a separate product. That reporting structure limits a clean standalone revenue history for the fixed-dose combination. The combined franchise experienced major erosion after generic losartan and losartan/hydrochlorothiazide products entered the U.S. market.
Current manufacturers generally do not disclose product-level revenue for losartan/hydrochlorothiazide because sales are embedded within broader generic portfolios. Financial performance depends on tablet volume, contract pricing, supply continuity, channel mix, and manufacturing costs. The product is unlikely to produce branded-drug economics unless a supplier obtains temporary scarcity pricing during a shortage.
When did losartan hydrochlorothiazide lose exclusivity?
U.S. market exclusivity ended after expiration of the principal losartan patent estate and associated regulatory protections. Generic losartan and losartan/hydrochlorothiazide products have been marketed for many years.
The relevant commercial sequence was:
| Event |
Approximate timing |
| Original losartan approval |
1990s |
| Hyzaar approval |
1990s |
| Core losartan patent expiry |
2010, subject to applicable patent and pediatric-extension details |
| Generic losartan entry |
Mid-to-late 2000s |
| Broad generic combination competition |
Late 2000s onward |
| Current status |
Mature multisource generic market |
The Orange Book identifies patents and regulatory exclusivities associated with approved drug products. For Hyzaar, the principal patent barriers are expired, and there is no current U.S. branded exclusivity that prevents ANDA competition for the established combination (FDA, n.d.-b).
What patents protect losartan potassium and hydrochlorothiazide?
The original patent estate covered losartan, pharmaceutical compositions, and related combinations. The most frequently cited core U.S. losartan patent is U.S. Patent No. 5,138,069, assigned to E. I. du Pont de Nemours and Company and associated with the losartan chemical entity. Its term expired in 2010, subject to statutory adjustments and any applicable pediatric extension.
Current patent position
| Patent category |
Current commercial relevance |
| Losartan active-ingredient patents |
Expired |
| Losartan composition patents |
Expired or no longer blocking routine generic entry |
| Losartan/hydrochlorothiazide combination patents |
Expired |
| Basic hydrochlorothiazide patents |
Expired |
| Branded formulation patents |
No material barrier to standard tablets |
| Method-of-use patents |
No known unexpired U.S. patent barrier that materially blocks ordinary generic use |
The practical patent estate is weak for standard losartan/hydrochlorothiazide tablets. A company developing an ordinary immediate-release generic is not confronting a meaningful composition-of-matter or formulation monopoly.
What is the Orange Book status of Hyzaar?
Hyzaar remains an FDA-approved reference product, but its Orange Book position does not create current market exclusivity comparable to a newly approved branded drug.
The relevant regulatory characteristics are:
- Hyzaar is associated with an approved NDA.
- Generic versions are approved through ANDAs referencing the relevant listed drug.
- The principal listed patents have expired.
- Standard generic entry is permitted subject to FDA approval, labeling requirements, bioequivalence, manufacturing compliance, and any applicable product-specific regulatory conditions.
- Orange Book listing does not itself establish that a patent remains enforceable or commercially blocking.
FDA’s Orange Book provides the official framework for listed drugs, therapeutic equivalence evaluations, and patent information submitted by sponsors (FDA, n.d.-b).
Which companies manufacture losartan hydrochlorothiazide?
The U.S. generic supply base has included major and mid-sized manufacturers such as:
- Teva Pharmaceuticals
- Torrent Pharmaceuticals
- Lupin
- Zydus Pharmaceuticals
- Dr. Reddy’s Laboratories
- Camber Pharmaceuticals
- Ingenus Pharmaceuticals
- Aurobindo Pharma
- Rising Pharmaceuticals
- Solco Healthcare
- Mylan, now part of Viatris, depending on product and market period
Availability differs by strength, National Drug Code, wholesaler, and time period. A company may retain an FDA-approved product while having limited commercial distribution.
The competitive landscape is fragmented. No single supplier generally controls the entire U.S. market, although a small number of manufacturers can account for a significant share of pharmacy-channel supply at a given time.
Which companies challenged the Hyzaar patents?
Generic applicants challenged or designed around the relevant patent estate through ANDA filings during the period when Hyzaar and losartan retained commercial value. Paragraph IV certifications are most relevant to the initial wave of generic entry, not to current market access.
A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Filing can trigger patent litigation and a potential 30-month stay of FDA approval under the Hatch-Waxman framework.
For losartan/hydrochlorothiazide, the litigation risk has largely passed because the principal patents expired. Current applicants generally face regulatory and manufacturing risks rather than meaningful patent litigation risk.
What patent litigation affected losartan and Hyzaar?
The principal disputes involved the validity, scope, and infringement of patents covering losartan and related pharmaceutical compositions. These disputes occurred during the transition from branded to generic supply.
The commercially important outcome was generic entry after expiration or resolution of the blocking patent estate. There is no widely recognized current U.S. patent litigation campaign that threatens routine generic manufacture of losartan/hydrochlorothiazide.
Settlement agreements
Generic settlements may have governed the timing of market entry for particular applicants. Such agreements can include:
- Agreed generic launch dates.
- Non-exclusive licenses.
- Authorized-generic arrangements.
- Restrictions tied to patent validity or infringement disputes.
The presence of historical settlement activity does not create current exclusivity once the underlying patents have expired.
What formulations are protected by losartan hydrochlorothiazide patents?
The standard immediate-release tablet is not protected by an active U.S. formulation monopoly. The commercial product uses conventional oral-tablet technology, and generic manufacturers can generally compete through bioequivalent formulations.
Potential technical differentiation can involve:
- Tablet hardness and disintegration.
- Excipient selection.
- Stability under humidity and temperature stress.
- Film coating.
- Manufacturing process controls.
- Packaging configurations.
- Impurity control.
- Dissolution performance.
These attributes can affect FDA approval, manufacturing cost, and supply reliability. They do not provide the same economic protection as an unexpired formulation patent.
Are there manufacturing or intellectual-property barriers?
Manufacturing barriers are moderate but manageable. The main risks are operational rather than patent-based.
Manufacturing risks
Manufacturers must control:
- Losartan-related impurities and degradation products.
- Hydrochlorothiazide assay and content uniformity.
- Dissolution across strengths.
- Moisture sensitivity and stability.
- Cross-contamination controls.
- Validated analytical methods.
- Compliance with current good manufacturing practice requirements.
Losartan recalls in the broader pharmaceutical supply chain have also highlighted the importance of nitrosamine risk management. FDA has investigated nitrosamine contamination involving certain ARB products, particularly valsartan, losartan, and related substances. Risk depends on active pharmaceutical ingredient source, manufacturing route, process controls, and batch testing (FDA, n.d.-c).
The result is a market where entry is legally open but operationally sensitive. A low-cost supplier can lose commercial position through a warning letter, recall, shortage, or inability to maintain consistent supply.
How does losartan hydrochlorothiazide compare with competing ARB combinations?
| Product |
Active ingredients |
Competitive position |
| Hyzaar/generic losartan-HCTZ |
Losartan plus hydrochlorothiazide |
Low-cost, mature, widely available |
| Diovan HCT/generic valsartan-HCTZ |
Valsartan plus hydrochlorothiazide |
Strong historical brand recognition; generic competition |
| Avalide/generic irbesartan-HCTZ |
Irbesartan plus hydrochlorothiazide |
Mature generic alternative |
| Benicar HCT/generic olmesartan-HCTZ |
Olmesartan plus hydrochlorothiazide |
Competes on formulary and prescriber preference |
| Micardis HCT/generic telmisartan-HCTZ |
Telmisartan plus hydrochlorothiazide |
Smaller but established segment |
| Losartan plus separate HCTZ |
Two tablets |
Often a low-cost substitute |
Losartan has a broad prescribing history and low generic cost. Its principal disadvantage is that it competes against several clinically familiar ARBs with similar fixed-dose options. The choice is often determined by formulary tier, prior patient response, renal considerations, prescriber habit, and inventory.
What generic launch scenarios exist?
Base case: stable multisource supply
The most likely scenario is continued availability from several generic manufacturers with modest annual price pressure. Prescription volume remains relatively stable, while revenue per tablet declines gradually.
Downside case: supplier consolidation
If manufacturers exit because of low margins, the market can become dependent on fewer suppliers. A plant shutdown, regulatory action, or API disruption could produce temporary shortages and short-term price increases.
Upside case: channel or contract expansion
A manufacturer with reliable supply, competitive pricing, and strong wholesaler contracts can increase share. The upside is volume-based rather than patent-based.
Low-probability case: new branded formulation
A reformulated product, extended-release system, or combination with an additional active ingredient could create a new intellectual-property opportunity. Such a product would compete against existing low-cost therapy and would require clinical, regulatory, and reimbursement differentiation.
What is the biosimilar risk for losartan hydrochlorothiazide?
There is no biosimilar risk. Losartan/hydrochlorothiazide is a chemically synthesized small-molecule tablet, not a biologic. Competition occurs through the ANDA generic pathway, not through the FDA biosimilar pathway under the Public Health Service Act.
The relevant competitive risks are generic substitution, authorized-generic supply, API sourcing, manufacturing compliance, and formulary contracting.
What is the geographic coverage of the patent estate?
The original losartan estate had international counterparts, but the relevant product is now broadly generic across major markets.
| Region |
Current commercial pattern |
| United States |
Multisource generic; core patents expired |
| European Union |
Generic and national-market competition |
| Canada |
Generic competition subject to national and provincial reimbursement |
| Japan |
Generic competition after local patent and regulatory expiries |
| India |
Large manufacturing base and domestic generic competition |
| Latin America |
Country-specific registration and pricing regimes |
| Emerging markets |
Variable availability, local tendering, and regulatory requirements |
Patent expiration does not guarantee simultaneous market entry in every country. Local registration, data exclusivity, compulsory licensing rules, procurement systems, and manufacturing approvals can affect timing.
What is the investment and licensing outlook?
The asset has limited value as a standalone licensing target. Commercial opportunity is concentrated in manufacturing scale, supply reliability, regional registration portfolios, and contract sales.
Potential transaction rationales include:
- Acquiring an established generic dossier.
- Expanding into a region where the product is not registered.
- Combining the product with a broader hypertension portfolio.
- Securing API or finished-dose capacity.
- Adding the product to a pharmacy or hospital tender portfolio.
A licensing transaction based solely on exclusivity would have weak economics because the core U.S. patent estate is expired. Value depends on net price, volume, manufacturing cost, regulatory status, and channel access.
Key Takeaways
- Losartan potassium and hydrochlorothiazide is a mature, multisource generic combination originally marketed as Hyzaar.
- U.S. composition, formulation, and principal patent barriers have expired.
- The product has no biosimilar pathway or current biologic-style exclusivity risk.
- Financial value is driven by chronic prescription volume, low manufacturing cost, supply reliability, and formulary access.
- Merck’s historical Cozaar and Hyzaar revenue was reported largely at the franchise level, limiting standalone Hyzaar revenue analysis.
- Current patent litigation risk is low; manufacturing, API, nitrosamine control, and shortage risks are more relevant.
- Generic pricing pressure is persistent, but temporary supply disruption can increase value for reliable manufacturers.
- The strongest commercial opportunities involve portfolio scale, regional registration, and dependable supply rather than patent licensing.
FAQs About Losartan Potassium and Hydrochlorothiazide
Is losartan hydrochlorothiazide still protected by patents?
No material U.S. patent barrier remains for the standard immediate-release combination. The principal losartan and combination patents expired, allowing broad generic competition.
Is Hyzaar still sold in the United States?
Hyzaar remains the reference brand, but prescribing and dispensing are dominated by generic losartan/hydrochlorothiazide products. Brand availability and commercial promotion can vary.
Can a company file a Paragraph IV challenge for losartan hydrochlorothiazide today?
A company can submit patent certifications as required for an ANDA, but the commercial value of a Paragraph IV strategy is limited when the relevant listed patents have expired or no longer block approval.
Why do losartan hydrochlorothiazide prices vary between pharmacies?
Prices vary because of manufacturer contracts, wholesaler discounts, insurance formularies, pharmacy purchasing arrangements, shortages, and differences among National Drug Codes and tablet strengths.
Does losartan hydrochlorothiazide have a shortage risk?
Yes. The molecule is not inherently scarce, but low generic margins and supplier concentration can create temporary shortages after manufacturing disruptions, regulatory actions, recalls, or API problems.
References
-
U.S. Food and Drug Administration. (n.d.-a). Hyzaar prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (n.d.-c). Nitrosamine impurity investigations and recalls. FDA.
-
Merck & Co., Inc. (2010). Annual report. Merck.
-
United States Patent and Trademark Office. (1992). U.S. Patent No. 5,138,069: Substituted imidazole compounds. U.S. Department of Commerce.
